Nuvectis Pharma, Inc. (NVCT)
23.73
-1.46
(-5.80%)
USD |
NASDAQ |
Aug 28, 16:00
23.62
-0.12
(-0.48%)
After-Hours: 20:00
Nuvectis Pharma Free Cash Flow : -19.51M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -19.51M |
| March 31, 2026 | -18.35M |
| December 31, 2025 | -16.01M |
| September 30, 2025 | -14.50M |
| June 30, 2025 | -12.41M |
| March 31, 2025 | -12.06M |
| December 31, 2024 | -12.25M |
| September 30, 2024 | -13.63M |
| June 30, 2024 | -14.47M |
| March 31, 2024 | -15.54M |
| Date | Value |
|---|---|
| December 31, 2023 | -15.95M |
| September 30, 2023 | -15.62M |
| June 30, 2023 | -16.80M |
| March 31, 2023 | -15.26M |
| December 31, 2022 | -13.56M |
| September 30, 2022 | -11.11M |
| June 30, 2022 | -11.11M |
| March 31, 2022 | -12.58M |
| December 31, 2021 | -9.504M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Decoy Therapeutics, Inc. | -8.367M |
| Unicycive Therapeutics, Inc. | -27.85M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -4.531M |
| Cash from Financing (Quarterly) | 1.561M |
| Free Cash Flow Per Share (Quarterly) | -0.193 |
| Free Cash Flow to Equity (Quarterly) | -4.531M |
| Free Cash Flow to Firm (Quarterly) | -4.531M |
| Free Cash Flow Yield | -3.45% |